Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation
Authors
Keywords
-
Journal
Cancer Medicine
Volume 8, Issue 5, Pages 2041-2055
Publisher
Wiley
Online
2019-04-06
DOI
10.1002/cam4.2087
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group
- (2018) Delphine Rea et al. CANCER
- Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan
- (2018) Naoto Takahashi et al. HAEMATOLOGICA
- Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
- (2018) Susanne Saussele et al. LANCET ONCOLOGY
- Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan
- (2018) Naoto Takahashi et al. HAEMATOLOGICA
- Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study
- (2017) Naoto Takahashi et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis
- (2017) Francis J. Giles et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia
- (2017) Gabriel Etienne et al. JOURNAL OF CLINICAL ONCOLOGY
- Remembrance of things past — discontinuation of second-generation TKI therapy for CML
- (2017) Timothy P. Hughes et al. Nature Reviews Clinical Oncology
- Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study
- (2016) Delphine Rea et al. BLOOD
- Moving treatment-free remission into mainstream clinical practice in CML
- (2016) Timothy P. Hughes et al. BLOOD
- RT-qPCR and RT-Digital PCR: A Comparison of Different Platforms for the Evaluation of Residual Disease in Chronic Myeloid Leukemia
- (2016) Mary Alikian et al. CLINICAL CHEMISTRY
- BCR-ABL1expression, RT-qPCR and treatment decisions in chronic myeloid leukaemia
- (2016) Susan Latham et al. JOURNAL OF CLINICAL PATHOLOGY
- The concept of treatment-free remission in chronic myeloid leukemia
- (2016) S Saußele et al. LEUKEMIA
- European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
- (2016) J L Steegmann et al. LEUKEMIA
- Best Practices in Chronic Myeloid Leukemia Monitoring and Management
- (2016) Simona Soverini et al. ONCOLOGIST
- Molecular monitoring in chronic myeloid leukemia--how low can you go?
- (2016) S. Branford Hematology-American Society of Hematology Education Program
- Deep molecular responses for treatment-free remission in chronic myeloid leukemia
- (2016) Stéphanie Dulucq et al. Cancer Medicine
- Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia
- (2015) N C P Cross et al. LEUKEMIA
- Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials
- (2015) Koji Sasaki et al. Lancet Haematology
- How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemia
- (2014) David M. Ross et al. BRITISH JOURNAL OF HAEMATOLOGY
- Considerations for Digital PCR as an Accurate Molecular Diagnostic Tool
- (2014) J. F. Huggett et al. CLINICAL CHEMISTRY
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
- (2013) M. Baccarani et al. BLOOD
- Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
- (2013) D. M. Ross et al. BLOOD
- Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience
- (2012) H. Kantarjian et al. BLOOD
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics
- (2012) Y Kanda BONE MARROW TRANSPLANTATION
- Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
- (2010) François-Xavier Mahon et al. LANCET ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now